Biological activity of placental protein 13
OwnerSveinbjorn Gizurarson, Hamutal Meiriinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and/or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and/or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and/or eclampsia.
Claims10
A method for treating a pregnancy associated disease selected from eclampsia and preeclampsia in a pregnant female person who is at risk of developing said pregnancy associated disease, comprising administering to said person a composition selected from human placental protein 13 (PP-13) and PEGylated human PP-13, wherein said administering is initiated during weeks 5-20 of pregnancy.
Dependencies are inferred from the claim text.